PRAX catalysts and FDA events, page 2.
Updated Snapshot 20261116T222116ZBuilt
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on PRAX PDUFA dates and upcoming catalysts. This page continues the list.
Past catalysts and FDA decisions (continued)
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| 2H 2025Half-year disclosed | vormatrigine (PRAX-628) | PRAX | Topline readout | treatment resistant FOS | Scheduled | SEC 8-K Exhibit 99.1 |
| May 2, 2025 | — | PRAX | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| May 2025Month disclosed | relutrigine (PRAX-562) | PRAX | Topline readout | — | Positive | SEC Form 10-Q |
| mid-2025Half-year disclosed | relutrigine (PRAX-562) | PRAX | Trial start | — | Scheduled | SEC 8-K Exhibit 99.1 |
| 1H 2025Half-year disclosed | elsunersen (PRAX-222) | PRAX | Trial start | — | Scheduled | SEC 8-K Exhibit 99.1 |
| 2025Year disclosed | relutrigine (PRAX-562) | PRAX | Topline readout | — | Scheduled | SEC Form 8-K |
| Q1 2025Quarter disclosed | — | PRAX | Interim readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| 1H 2025Half-year disclosed | — | PRAX | Topline readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
Every catalyst is quoted from PRAX’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.